NUVATION BIO NUVB 深 沪
交易中 05-20 10:52:01 美东时间
4.325
+0.085
+2.00%
华盛通- 最 高4.38
- 今 开4.29
- 成交量 83.64万股
- 最 低 4.235
- 昨 收 4.24
- 总市值 15.06亿
- 52周最高 9.75
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 1.57
- 委 比 18.98%
- 总股本 3.48亿
- 历史最高 15.23
- 量 比 0.96
- 振 幅 3.42%
- 历史最低 0.95
- 每 手 1
- 风险率 2.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel上调Lumentum控股目标价从800美元升至1100美元；Pinterest、先进能源工业、安森美半导体、莱迪思半导体、V2X等获多家大行上调目标价
今日重点评级关注：Piper Sandler：维持Aclaris Therapeutics"超配"评级，目标价从7美元升至11美元；Evercore ISI集团：维持BioMarin Pharmaceutical"跑赢大市"评级，目标价从110美元升至120美元
05-06 11:29
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:NUVB) with a Buy and maintains $17 price target.
05-05 18:26
财报速睇 | NUVATION BIO 2026财年Q1营收0.83亿美元，同比增长2598.7%；归母净利润0.05亿美元，扭亏为盈
华盛资讯5月5日讯，NUVATION BIO公布2026财年Q1业绩，公司Q1营收0.83亿美元，同比增长2598.7%，归母净利润0.05亿美元，扭亏为盈。
05-05 12:35
财报速睇 | NUVATION BIO 2026财年Q1营收0.83亿美元，同比增长2666.7%；归母净利润0.05亿美元，扭亏为盈
华盛资讯5月5日讯，NUVATION BIO公布2026财年Q1业绩，公司Q1营收0.83亿美元，同比增长2666.7%，归母净利润0.05亿美元，扭亏为盈。
05-05 04:46
Nuvation Bio Q1 EPS $0.01, Inline, Sales $83.228M Beat $62.259M Estimate.
Nuvation Bio (NYSE:NUVB) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 106.25 percent increase over losses of $(0.16) per share from the same period last year. The
05-05 04:13
Earnings Scheduled For May 4, 2026
Companies Reporting Before The Bell • Pulse Biosciences (NASDAQ:PLSE) is likely...
05-04 19:11
Nuvation Bio Reveals IBTROZI Showed Highly Durable Responses in Longer-Term Follow-Up Data From Pivotal Studies Presented At AACR 2026; IBTROZI Also Demonstrated A High Overall Response Rate In TKI-Naïve Patients At 89.8%; Preclinical Data Presented At AACR Showed Taletrectinib's Potential For Suppressing TrkB-mediated Lung Cancer Cell Migration
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the
04-22 06:04
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
Eisai, Nuvation Bio Announces European Medicines Agency Validate Marketing Authorisation Application For Taletrectinib To Treat ROS1-Positive Non-Small Cell Lung Cancer
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc.
03-27 04:25
Nuvation Bio Reports IBTROZI Achieves 50-Month Median Response In ROS1+ NSCLC, To Be Presented At AACR 2026
Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 months as of August
03-18 04:35
